A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: Sensitivity and specificity for the diagnosis of myocardial infarction

International Journal of Molecular Medicine

Volumn 35, Issue 1, 2015, Pages 72-80

  Lou, Xiaoli ^a   Hou, Yanqiang ^a   Liang, Dongyu ^a   Peng, Liang ^a   Chen, Hongwei ^a   Ma, Shanyuan ^a   Zhang, Lurong ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Alu; Cell free DNA; Myocardial infarction; Real time PCR

Indexed keywords

ALU DNA; ALU1 DNA; ALU2 DNA; ALU3 DNA; ALU4 DNA; ALU5 DNA; BIOLOGICAL MARKER; CARDIAC TROPONIN I; CELL FREE DNA; CREATINE KINASE MB; DNA; ISOENZYME; LACTATE DEHYDROGENASE; MYOGLOBIN; PRIMER DNA; TROPONIN I; UNCLASSIFIED DRUG;

ADULT; AGED; ALU BASED REAL TIME POLYMERASE CHAIN REACTION; ALU SEQUENCE; ALU1 SEQUENCE; ALU2 SEQUENCE; ALU3 SEQUENCE; ALU4 SEQUENCE; ALU5 SEQUENCE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA CONTENT; DNA DETERMINATION; DNA SEQUENCE; FEMALE; GENE CONTROL; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; HUMAN GENOME; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID AMPLIFICATION; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RESTRICTION SITE; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALU ELEMENTS; CASE-CONTROL STUDIES; DNA; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84917709184     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1991     Document Type: Article

References (48)

1. Jung K, Fleischlacker M and Rabien A: Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 411: 1611-1624, 2010.
2. Boddy JL, Gal S, Malone PR, Harris AL and Wainscoat JS: Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 11: 1394-1399, 2005.
3. Gautschi O, Bigosch C, Huegli B, et al: Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22: 4157-4164, 2004.
4. Jahr S, Hentze H, Englisch S, et al: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61: 1659-1665, 2001.
5. Goebel G, Zitt M and Müller HM: Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 21: 105-120, 2005.
6. Ellinger J, Wittkamp V, Albers P, et al: Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol 181: 363-371, 2009.
7. Schwarzenbach H, Stoehlmacher J, Pantel K and Goekkurt E: Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann NY Acad Sci 1137: 190-196, 2008.
8. Zachariah RR, Schmid S, Buerki N, et al: Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol 112: 843-850, 2008.
9. Zheng Z, Luo Y and McMaster GK: Sensitive and quantitative measurement of gene expression directly from a small amount of whole blood. Clin Chem 52: 1294-1302, 2006.
10. Hwu HR, Roberts JW, Davidson EH and Britten RJ: Insertion and/or deletion of many repeated DNA sequences in human and higher ape evolution. Proc Natl Acad Sci USA 83: 3875-3879, 1986.
11. Lander ES, Linton LM, Birren B, et al: Initial sequencing and analysis of the human genome. Nature 409: 860-921, 2001.
12. Mandel P and Metais P: Les acides nucleiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 142: 241-243, 1948.
13. Gormally E, Caboux E, Vineis P and Hainaut P: Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635: 105-117, 2007.
14. Lam NY, Rainer TH, Chan LY, Joynt GM and Lo YM: Time course of early and late changes in plasma DNA in trauma patients. Clin Chem 49: 1286-1291, 2003.
15. Zhong XY, Laivuori H, Livingston JC, et al: Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol 184: 414-419, 2001.
16. Galeazzi M, Morozzi G, Piccini M, et al: Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders. Autoimmun Rev 2: 50-55, 2003.
17. Jylhävä J, Jylhä M, Lehtimäki T, Hervonen A and Hurme M: Circulating cell-free DNA is associated with mortality and inflammatory markers in nonagenarians: the Vitality 90+ Study. Exp Gerontol 47: 372-378, 2012.
18. Jylhävä J J, Nevalainen T, Marttila S, et al: Characterization of the role of distinct plasma cell-free DNA species in age-associated inflammation and frailty. Ageing Cell 12: 388-397, 2013.
19. Nicolaides KH, Wright D, Poon LC, Syngelaki A and Gil MM: First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 42: 41-50, 2013.
20. Johnson J, Pastuck M, Metcalf A, et al: First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. Prenatal Diagnosis 33: 1-6, 2013.
21. Moreira VG, Prieto B, Rodríguez JS and Alvarez FV: Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients Ann Clin Biochem 47: 253-258, 2010.
22. Gao YJ, He YJ, Yang ZL, et al: Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med 48: 1651-1656, 2010.
23. Saukkonen K1, Lakkisto P, Pettilä V, Varpula M, Karlsson S, Ruokonen E and Pulkki K; Finnsepsis Study Group: Cell-free plasma DNA as a oredictor of outcome in severe sepsis and septic shock. Clin Chem 54: 1000-1007, 2008.
24. Rhodes A, Wort SJ, Thomas H, Collinson P and Bennett ED: Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care 10: R60, 2006.
25. Huttunen R, Kuparinen T, Jylhävä J, et al: Fatal outcome in bacteremia is characterized by high plasma cell free DNA concentration and apoptotic DNA fragmentation : a prospective cohort study. PLoS One 6: e21700, 2011.
26. Mosca M, Giuliano T, Cuomo G, et al: Cell-free DNA in the plasma of patients with systemic sclerosis. Clin Rheumatol 28: 1437-1440, 2009.
27. Zanetti-Dällenbach RA, Schmid S, Wight E, et al: Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Int J Biol Markers 22: 95-99, 2007.
28. Zhong XY, Ladewig A, Schmid S, et al: Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet 276: 327-331, 2007.
29. Chen JA, Meister S, Urbonaviciute V, et al: Sensitive detection of plasma/serum DNA in patients with systemic lupus erythematosus. Autoimmunity 40: 307-310, 2007.
30. Zhong XY, von Mühlenen I, Li Y, et al: Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Clin Chem 53: 1609-1614, 2007.
31. Chang CP, Chia RH, Wu TL, et al: Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin Chim Acta 327: 95-101, 2003.
32. Beck J, Urnovitz HB, Riggert J, et al: Profile of the circulating DNA in apparently healthy individuals. Clin Chem 55: 730-738, 2009.
33. Shukla D, Kale AD, Hallikerimath S, Yerramalla V and Subbiah V: Can quantifying free-circulating DNA be a diagnostic and prognostic marker in oral epithelial dysplasia and oral squamous cell carcinoma? J Oral Maxillofac Surg 71: 414-418, 2013.
34. Cepika AM, Soldo Jureša D, Morović Vergles J, et al: Decrease in circulating DNA, IL-10 and BAFF levels in newly-diagnosed SLE patients after corticosteroid and chloroquine treatment. Cell Immunol 276: 196-203, 2012.
35. Catarino R, Coelho A, Araújo A, et al: Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PLoS One 7: e38559, 2012.
36. Szpechcinski A, Chorostowska-Wynimko J, Kupis W, et al: Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC. Expert Opin Biol Ther 12 (Suppl 1): 3-9, 2012.
37. Huang Z, Hua D, Hu Y, et al: Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma. Pathol Oncol Res 18: 271-276, 2012.
38. Liggett T, Melnikov A, Yi QL, et al: Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 116: 1674-1680, 2010.
39. Horlitz M, Lucas A and Sprenger-Haussels M: Optimized quantification of fragmented, free circulating DNA in human blood plasma using a calibrated duplex real-time PCR. PLoS One 4: e7207, 2009.
40. Szpechcinski A, Struniawska R, Zaleska J, et al: Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. J Physiol Pharmacol 59 (Suppl 6): 675-681, 2008.
41. Sang F and Ren J: Comparisons between capillary zone electrophoresis and real-time PCR for quantification of circulating DNA levels in human sera. J Chromatogr B Analyt Technol Biomed Life Sci 838: 122-128, 2006.
42. Jing RR, Wang HM, Cui M, et al: A sensitive method to quantify human cell-free circulating DNA in blood: relevance to myocardial infarction screening. Clin Biochem 44: 1074-1079, 2011.
43. Yeh RW, Sidney S, Chandra M, et al: Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362: 2155-2165, 2010.
44. Thygesen K, Alpert JS and White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. J Am Coll Cardiol 50: 2173-2195, 2007.
45. Cui M, Fan M, Jing R, et al: Cell-free circulating DNA: a new biomarker for the acute coronary syndrome. Cardiology 124: 76-84, 2013.
46. Destouni A, Vrettou C, Antonatos D, et al: Cell-free DNA levels in acute myocardial infarction patients during hospitalization. Acta Cardiol 64: 51-57, 2009.
47. Antonatos D, Patsilinakos S, Spanodimos S, et al: Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann NY Acad Sci 1075: 278-281, 2006.
48. Shimony A, Zahger D, Gilutz H, et al: Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients. Acute Card Care 12: 109-111, 2010.